Clinical trials: Paclitaxel, completed
Coronary Artery Disease
Synergy Between Stent and Drugs to Avoid Ischemic Recurrences After Percutaneous Coronary Intervention
The duration of dual antiplatelet treatment (i.e. asprin and clopidogrel) after drug-eluting stent implantation is highly debated.
- Trial name
- PRODIGY (NCT00611286)
- Testing
- clopidogrel treatment after bare metal stent implantation, clopidogrel after zotarolimus-eluting stent implantation, clopidogrel after paclitaxel-eluting stent implantation
- Where
- Italy
- Volunteers
- 1,700 people
- Sponsor
- Marco Valgimigli
Arterial Occlusive Disease
Infrapopliteal Drug Eluting Angioplasty Versus Stenting
In total 50 patients diagnosed with long-segment infrapopliteal arterial disease will be randomized in two groups. The patients randomized in the Drug coated balloons (DCB) study arm will undergo a percutaneous transluminal…
- Trial name
- IDEAS-I (NCT01517997)
- Testing
- Paclitaxel coated balloon angioplasty., Infrapopliteal Primary Drug Eluting Stenting
- Where
- Greece
- Volunteers
- 50 people
- Sponsor
- University of Patras
Advanced Solid Tumors
A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors
This open-label, multicenter, dose-escalation study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of RO5509554 in participants with advanced solid tumors which are not amenable to standard treatment.
- Trial name
- NCT01494688
- Testing
- Paclitaxel, RO5509554
- Where
- 7 sites in United States, France
- Volunteers
- 217 people
- Sponsor
- Hoffmann-La Roche
Ovarian Neoplasms
Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib
This is a Phase II, randomized, multi-centre study aiming at comparing the efficacy of Olaparib and Cediranib vs. weekly Paclitaxel in terms of progression free survival (PFS) in platinum refractory or resistant recurrent ovarian…
- Trial name
- BAROCCO (NCT03314740)
- Testing
- Paclitaxel, Cediranib, Olaparib
- Where
- 6 sites in Italy
- Volunteers
- 123 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Head and Neck Cancer
A Phase I Trial of Abraxane, Cisplatin and 5-Fluorouracil Along With Chemoradiotherapy in Advanced Head and Neck Cancer
The purpose of this study is to determine the highest dose of a ABI-007 that can be given with cisplatin and 5-fluorouracil without causing intolerable side effects in patients with advanced head and neck cancer.
- Trial name
- NCT00731380
- Testing
- ABI-007
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as luteinizing hormone-releasing hormone agonist, flutamide, and bicalutamide may stop the adrenal glands from producing androgens.
- Trial name
- NCT00030654
- Testing
- bicalutamide, docetaxel, doxorubicin hydrochloride
- Where
- 78 sites in United States, Australia and 2 more
- Volunteers
- 21 people
- Sponsor
- Radiation Therapy Oncology Group
Advanced Tumors
Phase I Clinical Trial of CDP1 in Patients With Advanced Solid Tumors
The main purpose of this study was to evaluate the safety and tolerability of CDP1 in patients with advanced solid tumor, to explore dose limited toxicity (DLT), and to determine the recommended dose (RP2D) for phase II clinical…
- Trial name
- NCT04151810
- Testing
- CDP1, TIP chemotherapy
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Dragonboat Biopharmaceutical Company Limited
Malignant Airway Obstruction Secondary to Non-small Cell Lung Cancer
Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction Patients
Assess the safety and feasibility of local oncological drug delivery into the bronchial wall after recanalization of subjects with malignant airway obstruction. Safety and feasibility (technical success) will be assessed.
- Trial name
- BROADWAY (NCT02066103)
- Testing
- Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Mercator MedSystems, Inc.
Pancreatic Cancer Non-resectable
Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer
This is a Phase 3, randomized, double-blind trial to evaluate the efficacy and safety of neoadjuvant treatment with pamrevlumab or placebo in combination with either gemcitabine plus nab-paclitaxel (G/NP) or FOLFIRINOX in the…
- Trial name
- LAPIS (NCT03941093)
- Testing
- Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX
- Where
- 90 sites in United States, Austria and 10 more
- Volunteers
- 284 people
- Sponsor
- Kyntra Bio
Breast Cancer
A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab
To verify that combination therapy with trastuzumab + pertuzumab + eribulin brings similar PFS and better QOL compared to trastuzumab + pertuzumab + taxane in advanced/recurrent HER2-positive breast cancer patients who have no…
- Trial name
- NCT03264547
- Testing
- Pertuzumab, Trastuzumab, Docetaxel
- Where
- 2 sites in Japan
- Volunteers
- 446 people
- Sponsor
- Japan Breast Cancer Research Group
Lung Cancer
A Study With Tarceva and Chemotherapy vs. Chemotherapy Alone in Patients With Advanced Lung Cancer
The purpose of this study is to determine if Tarceva plus standard chemotherapy is more effective than standard chemotherapy alone in the treatment of lung cancer.
- Trial name
- NCT00047736
- Testing
- Tarceva (erlotinib HCl)
- Where
- 2 sites in United States
- Sponsor
- Genentech, Inc.
Pain
Auranofin in Decreasing Pain in Patients With Paclitaxel-Induced Pain Syndrome
This randomized pilot clinical trial studies whether auranofin will relieve pain following paclitaxel in patients who have previously experienced paclitaxel-induced pain.
- Trial name
- NCT02063698
- Testing
- auranofin, questionnaire administration
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Ovarian Cancer
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
This trial will compare the efficacy and toxicity of standard first-line chemotherapy alone vs. standard chemotherapy plus sorafenib in patients with stage III/IV ovarian cancer following cytoreductive surgery.
- Trial name
- NCT00390611
- Testing
- Sorafenib, Paclitaxel, Carboplatin
- Where
- 17 sites in United States
- Volunteers
- 85 people
- Sponsor
- SCRI Development Innovations, LLC
Melanoma
A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma
The objectives of this study are to compare the anti-tumor activity as measured by Progression Free Survival (PFS) and tolerability of Sorafenib in combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin in…
- Trial name
- NCT00111007
- Testing
- Sorafenib (Nexavar, BAY43-9006), Carboplatin/Paclitaxel
- Where
- 66 sites in United States, Australia and 5 more
- Volunteers
- 270 people
- Sponsor
- Bayer
Metastatic Breast Cancer
Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer
To determine the safety and tolerability of Oraxol as compared to IV paclitaxel in metastatic breast cancer
- Trial name
- NCT02594371
- Testing
- Oraxol, IV paclitaxel
- Where
- 45 sites in Argentina, Chile and 8 more
- Volunteers
- 402 people
- Sponsor
- Athenex, Inc.
Pancreatic Cancer
A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer
This is a dose escalation trial to evaluate the safety of stereotactic body radiotherapy (SBRT) delivered in 3 fractions for patients with locally advanced pancreatic cancer (LAPC) who have received induction chemotherapy…
- Trial name
- NCT02873598
- Testing
- FOLFIRINOX or gemcitabine/abraxane, SBRT
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Colorado, Denver
Germ Cell Tumor, Yolk Sac Tumor
Thalidomide Combined With Chemotherapy in the Treatment of Relapsed or Refractory Yolk Sac Tumor
Remarkable progress has been made in treating germ-cell tumor (GCT) through the use of platinum-based regimens. However, part of yolk sac tumor (YST) with cisplatin resistance or recurrence is nevertheless prone to relapse after…
- Trial name
- NCT06470464
- Testing
- Thalidomide combined with TGA chemotherapy (nab-paclitaxel + gemcitabine+ epirubicin)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shandong First Medical University
Epithelial Ovarian Cancer, Fallopian Tube Cancer
A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
This is a Phase 1 study during which patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer will receive investigational study drug MEK162 and paclitaxel.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT01649336
- Testing
- MEK162, MEK inhibitor; oral, Paclitaxel, mitotic inhibitor; intravenous
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
Carcinoma, Non Small Cell Lung (NSCLC)
Locally Advanced NSCLC Hyperfractionated RT
This is a prospective phase II study designed to evaluate an accelerated and adaptive RT approach for locally-advanced non-small cell lung cancer (NSCLC).
- Trial name
- ADAPT (NCT03128008)
- Testing
- Carboplatin, Paclitaxel, Daily hyperfractionated radiation therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Duke University
Adult Solid Neoplasm, Estrogen Receptor Negative
Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors
This phase I clinical trial studies the side effects and the best dose of veliparib when given together with carboplatin and paclitaxel in treating patients with locally advanced or metastatic solid tumors.
- Conditions
- Adult Solid Neoplasm, Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative
- Trial name
- NCT01281150
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.